CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,333,672 | -24.6% | 411,834 | -7.0% | 0.00% | -33.3% |
| Q2 2023 | $15,027,597 | +16.0% | 442,900 | +23.0% | 0.00% | 0.0% |
| Q1 2023 | $12,959,024 | -35.3% | 360,173 | -19.9% | 0.00% | -25.0% |
| Q4 2022 | $20,037,959 | +7.3% | 449,584 | -32.3% | 0.00% | 0.0% |
| Q3 2022 | $18,677,000 | +57.5% | 664,431 | +51.1% | 0.00% | +33.3% |
| Q2 2022 | $11,855,000 | +14.7% | 439,712 | +44.9% | 0.00% | +50.0% |
| Q1 2022 | $10,335,000 | +5.2% | 303,419 | +19.4% | 0.00% | 0.0% |
| Q4 2021 | $9,823,000 | -40.9% | 254,214 | -17.4% | 0.00% | -50.0% |
| Q3 2021 | $16,612,000 | +46.9% | 307,679 | -9.0% | 0.00% | +33.3% |
| Q2 2021 | $11,305,000 | +17.0% | 338,055 | -27.9% | 0.00% | +50.0% |
| Q1 2021 | $9,659,000 | -14.2% | 468,881 | -27.0% | 0.00% | -33.3% |
| Q4 2020 | $11,253,000 | +635.0% | 642,303 | +522.0% | 0.00% | – |
| Q3 2020 | $1,531,000 | – | 103,257 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |